2-({5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl}methyl)-tetrahydrofuran-2-carboxylic acid | 784147-67-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-({5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl}methyl)-tetrahydrofuran-2-carboxylic acid
• 英文别名: 2-((5-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid；2-[[5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl]methyl]oxolane-2-carboxylic acid
• CAS: 784147-67-7
• 化学式: C₂₃H₂₄N₂O₅
• 分子量: 408.454
• InChiKey: OYWWKKYTRPWVCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  94.7
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-({5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl}methyl)-tetrahydrofuran-2-carboxylic acid 生成 (S)-2-((5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid 、 (R)-2-((5-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)pyridin-2-yl)methyl)-tetrahydrofuran-2-carboxylic acid
  参考文献：
  名称：

  Pyridine-2-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

  摘要：

  A series of novel pyridine-2-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARalpha/gamma agonists with varied isoform selectivity. Based on the results of efficacy studies in diabetic (db/db) mice, and the desired pharmacokinetic parameters, compound (S)-13 was selected for further profiling.

  DOI：

  10.1016/j.bmcl.2006.08.105
• 作为产物：
  描述：

  ethyl 2-({5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl}methyl)tetrahydrofuran-2-carboxylate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 16.0h， 生成 2-({5-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-2-yl}methyl)-tetrahydrofuran-2-carboxylic acid
  参考文献：
  名称：

  Pyridine-2-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

  摘要：

  A series of novel pyridine-2-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARalpha/gamma agonists with varied isoform selectivity. Based on the results of efficacy studies in diabetic (db/db) mice, and the desired pharmacokinetic parameters, compound (S)-13 was selected for further profiling.

  DOI：

  10.1016/j.bmcl.2006.08.105

文献信息

• Alpha substituted carboxylic acids
  申请人：Su Guo Wei

  公开号：US20050187266A1

  公开（公告）日：2005-08-25

  Alpha substituted carboxylic acids of formula (I): wherein R 1 and R 2 are as defined in the specification and R 3 is wherein Y, Ar 1 , Ar 2 , Ar 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 9a , R 10 , R 11 , R 12 , R 17 , ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α/γ related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

  式(I)的α取代羧酸，其中R1和R2如规范中定义，R3为，其中Y、Ar1、Ar2、Ar3、R4、R5、R6、R7、R8、R9、R9a、R10、R11、R12、R17、环A和p如规范中定义；含有所述化合物或其盐的有效量的药物组合物对于治疗PPAR，特别是PPAR α/γ相关疾病，如糖尿病、血脂异常、肥胖和炎症性疾病是有用的。
• [EN] ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS<br/>[FR] ACIDES CARBOXYLIQUES ALPHA-SUBSTITUES COMME MODULATEURS DU RECEPTEUR ACTIVE PAR LES PROLIFERATEURS DE PEROXYSOME (PPAR)
  申请人：PFIZER

  公开号：WO2004092145A1

  公开（公告）日：2004-10-28

  Alpha substituted carboxylic acids of formula (I): wherein R' and R2 are as defined in the specification and R3 is A) formula (II); B) formula (III); C) formula (IV); and D) formula (V); wherein Y, Art, Are, AP, R4, R5, R6, R7, R6, R9, R9a, R10, R', R12, R17, ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α/y related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

  式(I)的α-取代羧酸，其中R'和R2如规范中定义，R3为A)式(II)；B)式(III)；C)式(IV)；和D)式(V)；其中Y、Art、Are、AP、R4、R5、R6、R7、R6、R9、R9a、R10、R'、R12、R17、环A和p如规范中定义；含有所述化合物或其盐的有效量的药物组合物对于治疗PPAR，特别是PPAR α/y相关的疾病，如糖尿病、血脂异常、肥胖和炎症性疾病是有用的。
• EP1615899A1
  申请人：——

  公开号：EP1615899A1

  公开（公告）日：2006-01-18
• Pyridine-2-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents
  作者：Paul S. Humphries、Jonathon V. Almaden、Sandra J. Barnum、Thomas J. Carlson、Quyen-Quyen T. Do、James D. Fraser、Mary Hess、Young H. Kim、Kathleen M. Ogilvie、Shaoxian Sun

  DOI：10.1016/j.bmcl.2006.08.105

  日期：2006.12

  A series of novel pyridine-2-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARalpha/gamma agonists with varied isoform selectivity. Based on the results of efficacy studies in diabetic (db/db) mice, and the desired pharmacokinetic parameters, compound (S)-13 was selected for further profiling.